Management

In This Section

Prior to Novelion, Michael Price was most recently vice president and chief financial officer for Noven Pharmaceuticals, Inc., a NASDAQ-listed company until its acquisition by Hisamitsu Pharmaceutical Company. Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. In his role at Noven, Mr. Price was directly involved with the development and execution of strategy that scaled the Company's commercial organization and significantly increased revenues. Prior to Noven, Mr. Price was vice president, chief financial officer, treasurer, secretary and a member of the board of directors for Bentley Pharmaceuticals, a New York Stock Exchange-listed company until Teva Pharmaceutical Industries' 2008 acquisition. Mr. Price is a certified public accountant. He holds a bachelor of science degree in business administration (accounting) from Auburn University and a master of business administration degree from Florida State University.

Jeffrey Hackman was most recently senior vice president, head of the US Internal Medicine and Oncology franchises for Shire. In this role, Mr. Hackman was a member of the US commercial leadership team and was responsible for sales, marketing, business insights and analytics for eight licensed products within Shire’s US rare disease portfolio. Prior to joining Shire, Mr. Hackman was vice president and region head for North America at Baxalta US, where he was responsible for building the oncology commercial division. Before that, Mr. Hackman was senior vice president of commercial operations, chief operating officer and board member at Sigma-Tau and Sigma-Tau Health Sciences USA.  Mr. Hackman has also held senior commercial leadership positions with Intercell AG, Emergent Biosolutions, MedImmune and Sanofi Pasteur. Mr. Hackman has a bachelor of arts degree in communications from Lycoming College.

Ben Harshbarger previously served as General Counsel for Aegerion Pharmaceuticals since September 2016. Prior to that, he served as Aegerion’s Acting General Counsel, VP, EMEA Legal Counsel and as our VP, Deputy General Counsel of Aegerion. Before joining Aegerion, Mr. Harshbarger served as Senior Director, Corporate Counsel at Cubist Pharmaceuticals, Inc. from March 2008 to March 2012, and Senior Director, Deputy General Counsel at ViaCell, Inc. from March 2006 to March 2008. Mr. Harshbarger served in several legal positions of increasing responsibility at Biogen Idec from November 2001 to March 2006 and served as an associate at the law firm of Mintz Levin from 1996 to 2001. Mr. Harshbarger holds a J.D. from Boston College Law School and a B.A. from the University of Richmond.

Roger Louis served as Aegerion Pharmceuticals' Senior Vice President, Global Chief Compliance Officer since November 2015. Mr. Louis has extensive experience in compliance and risk management, having served most recently as Senior Vice President, Compliance & Risk Management, Chief Compliance Officer at Cubist Pharmaceuticals prior to its acquisition by Merck. Mr. Louis joined Cubist from Biogen Idec where he was Senior Vice President, Chief Compliance Officer. From 1997 to 2012, he held positions of increasing responsibility at Genzyme Corporation, including Senior Vice President, Chief Compliance Officer. Mr. Louis began his legal career as an Associate at Hale & Dorr in Boston where he practiced corporate and securities law. Mr. Louis received his J.D. from University of Chicago School of Law and his B.A. from Tufts University.

Dr. Stewart joins Novelion from GlaxoSmithKline (GSK)  where he was chief medical officer with global responsibility for patient well-being across the vaccines, pharmaceutical and consumer business units. He joined GSK in 2000 as associate director for clinical research & development in the UK and has since held a variety of positions within GSK, primarily in R&D. He was previously clinical head of the biopharm unit and also therapy area head for the cardiovascular and metabolic therapy areas.  Prior to joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and was consultant physician/honorary senior lecturer and head of clinical services at the Diabetes Centre, Newcastle upon Tyne in the United Kingdom (UK).  His research was in lipid metabolism in type 2 diabetes. Dr. Stewart completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.

Prior to Novelion, Linda Buono joined Aegerion in July 2016 as Senior Vice President of Human Resources. Prior to Aegerion, Linda spent more than 25 years at Immunogen where she held a variety of leadership positions in Human Resources. Linda is effective in managing all the critical tasks and responsibilities of the company’s HR function and has facilitated recruitment of top talent across the organization. Importantly, she possesses the critical soft skills needed to significantly improve the success of the company. Her core attributes include courage, judgment, influence, political agility and effective communication, all of which are having an impact on the improved culture of the organization.